Aflibercept-ayyh (aflibercept 2 mg biosimilar) for treatment-naïve retinal vascular diseases: early real-world experience - the APEX study
{{output}}
Purpose: To evaluate the early real-world efficacy of intravitreal aflibercept 2 mg biosimilar (aflibercept-ayyh, Pavblu, Amgen, USA.) across common retinal vascular diseases in treatment-naïve eyes. ... ...
